68P - The utility of actinin-4 protein overexpression as a predictive biomarker for therapeutic effect of adjuvant chemotherapy to the resected lung adeno...

Date 17 April 2015
Event ELCC 2015
Session Poster lunch
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Early Stage
Translational Research
Presenter Hideaki Shiraishi
Citation Annals of Oncology (2015) 26 (suppl_1): 18-23. 10.1093/annonc/mdv048
Authors H. Shiraishi1, Y. Fujiwara2, T. Kakuya3, K. Tsuta4, S. Watanabe5, W. Huang6, T. Yamada3, H. Asamura7, Y. Ohe8, K. Honda3
  • 1Thoracic Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 2Experimental Therapeutics, Exploratory Oncology Research & Clinical Trial Center (epoc), Thoracic Oncology, National Cancer Center Hospital, Tokyo/JP
  • 3Chemotherapy And Clinical Research, National Cancer Center Research Institute, Tokyo/JP
  • 4Pathology And Clinical Laboratory, National Cancer Center Hospital, Tokyo/JP
  • 5Thoracic Surgery, National Cancer Center Hospital, Tokyo/JP
  • 6Ceo, Abnova Corporation, Taipei/TW
  • 7Thoracic Surgery, Keio University School of Medicine, Tokyo/JP
  • 8Thoracic Oncology, National Cancer Center Hospital, Tokyo/JP



Despite patients with adenocarcinoma of the lung undergoing adjuvant chemotherapy after curative surgery, some patients relapse with the cancer. Although some reports have revealed the benefits of adjuvant chemotherapy for stage-II and stage-IIIA, predictive biomarkers for efficacy of adjuvant chemotherapy have not yet been sufficiently identified.


The protein expression level of actinin-4 in 149 patients with stage-II and –IIIA adenocarcinoma of the lung was checked by immunohistochemistry (IHC). The data of expression of actinin-4 protein was compared to the prognosis between adjuvant chemotherapy and observation, retrospectively.


149 patients were classified into the positive cases (IHC-positive group, n = 75) and negative cases (IHC-negative group, n = 73) of actinin-4 by IHC. The patients of the IHC-positive group received more benefit from adjuvant chemotherapy than those under observation (hazard ratio; HR: 0.307, p = 0.028 cox regression analysis). In contrast, the patients of the IHC-negative group received no benefits from adjuvant chemotherapy, compared with those under observation (HR; 0.926, p = 0.876).


Overexpression of actinin-4 is a predictive biomarker for the efficacy of adjuvant chemotherapy for patients with adenocarcinoma of the lung of stage-II and IIIA.


All authors have declared no conflicts of interest.